Microfluidic Cell Sorting Patents: Leaders & White Space 2026
A data-backed view of microfluidic cell sorting patents: filing trends since 2017, the concentration of filings among leading assignees, IPC technology composition, and where claim space remains open.
Filing growth = 2021 (108 records) → 2024 (86); 2024 is the last year we treat as complete. Top-5 share = the 5 largest assignees ÷ all 1,833 records in scope (CR5), not the ranked leaders only.
What the microfluidic cell sorting patent record shows
Microfluidic cell sorting sits at the intersection of lab apparatus, molecular diagnostics and genetic analysis. The dataset behind this page covers 1,833 patent records published between 2015 and the 2026 cut-off, drawn from title-and-abstract mentions of microfluidic cell sorting together with claims language that ties cell sorting or classification to a microfluidic or lab-on-a-chip context. That claims-level search string means the records skew toward documents that actually stake a technical position on sorting mechanics, not just adjacent lab-on-a-chip work.
Filing activity rose through the mid-2010s, peaked in 2018, and has since eased — annual filing dropped 20% from 108 in 2021 to 86 in 2024, the last year the data can treat as complete given an 18-month publication lag. Reading 2025 and 2026 as decline would be premature; those years are still filling in.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
Two views of the same 1,833-record dataset: how filing volume moved year over year, and how records distribute across IPC subclasses.
A 2018 peak followed by a real pull-back
Filings hit 148 in 2018, the high point of the series. By 2024, the most recent complete year, annual volume had fallen to 86 — down 20% from 108 in 2021. That is a genuine slowdown in new filing activity from the leaders and the long tail alike, not a data artefact; treat 2025 and 2026 figures as understated rather than as continuing the decline.
Publication lags filing by roughly 18 months, so 2025 onwards are still filling in. Growth rates on this page therefore end at 2024; running them to the last bar would understate the field.
Analytical readout dominates the claim space
G01N (material analysis and testing) appears in 57.7% of the 1,833 records, well ahead of C12Q (enzyme/DNA testing, 28.5%) and B01L (lab apparatus, 25.0%). C12N (microorganisms and genetic engineering, 23.8%) and C12M (bioreactors, 14.0%) trail behind. Because a single record can carry several IPC classes, these shares sum to more than 100% — they describe overlap, not a partition of the field.
Shares are the percentage of the 1,833 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Lab-on-a-Chip & Microfluidics: Microfluidic Cell Sorting Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about lab-on-a-chip & microfluidics: microfluidic cell sorting patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited foundations and a representative claim
SG165165A1 — Method and apparatus for sorting particles
A method and apparatus of isolating a subpopulation of cells from a cell population using a microfluidic cell sorting device. The method and apparatus identify cells that have a desired phenotype from a population in a mixture and isolate the cells from cells that do not have the desired phenotype using a microfluidic cell sorting device. The isolated cells having the desired phenotype are passed to a mixing and incubation region of the microfluidic cell sorting device, where a test compound is introduced.Filed by Cytonome/ST — a phenotype-based isolation and downstream test-compound mixing claim that sits close to the core of the sorting-and-assay workflow many later filers had to design around.
View full record| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US20040072278A1 | Microfluidic particle-analysis systems | 874 |
| 2 | US20060078888A1 | In vitro evolution in microfluidic systems | 436 |
| 3 | US20050287572A1 | Microfabricated integrated DNA analysis system | 404 |
| 4 | US20050221339A1 | Compartmentalised screening by microfluidic control | 404 |
| 5 | US20090035770A1 | Inline-injection microdevice and microfabricated integrated DNA analysis system using same | 359 |
| 6 | WO2016138496A1 | Spatially addressable molecular barcoding | 333 |
| 7 | WO2016126871A2 | Sequencing of nucleic acids via barcoding in discrete entities | 332 |
| 8 | WO2006040551A2 | Compartmentalised screening by microfluidic control | 308 |
| 9 | US7312085B2 | Microfluidic particle-analysis systems | 293 |
| 10 | US20120122084A1 | System for identifying and sorting living cells | 260 |
Citation counts favour older documents inside any searched corpus — they signal influence on later filers, not current commercial weight.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Four read-outs from the same dataset, each pointing at a different practical question: where the field is crowded, where it has cooled, and who tends to file together.
The top of the field is concentrated, the rest is a long tail
The five leading assignees combined hold 25.0% of all 1,833 records in scope, with the single leader at 196 records. Move past the top ten — 32.0% combined — and the ranking thins quickly into single- and few-filing entrants across the other 90 ranked companies.
Volume has genuinely eased from its 2018 peak
After peaking at 148 filings in 2018, annual output fell 20% between 2021 and 2024, the last year the record can be read as complete. That is a real cooling in new filing, not an artefact of publication lag — though 2025-2026 figures will still rise as they finish filling in.
Sorting claims lean on analytical measurement, not just fluidics
G01N (material analysis and testing) touches more than half the dataset, ahead of C12Q enzyme/DNA testing and B01L lab apparatus. That pattern says most sorting claims are written to protect what happens to the cell after separation — the measurement or assay step — as much as the sorting mechanism itself.
A handful of institutional pairings recur
Ten co-assignee pairs appear in the dataset, with the strongest pairings linking research institutes to affiliated foundations or hospital systems. That pattern points to joint academic-industry or academic-hospital filing programmes rather than broad industry consortia.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to lab-on-a-chip & microfluidics: microfluidic cell sorting patent landscape, with the prior art for and against each one.
Where to take this analysis
The dataset points to specific next questions for a freedom-to-operate review or a filing strategy.
Map claim scope against the leader's portfolio
With the top assignee alone holding 196 records, a claims-level comparison against that portfolio is the fastest way to see which sorting mechanisms are already occupied and which are not.
Explore assignee portfolios in EurekaTrack the post-2024 filing signal as it fills in
2025 and 2026 figures are still incomplete due to publication lag. Re-running the trend view in six months will show whether the 2021-2024 pull-back continued or reversed.
Set up a filing-trend alert in EurekaTest under-claimed IPC combinations
Classes like C40B combinatorial libraries (8.0%) and C07K peptides (6.5%) sit far below G01N and C12Q. Cross-referencing these against sorting claims can surface genuinely under-claimed technical combinations.
Run an IPC white-space search in EurekaCommon questions about microfluidic cell sorting patents
The dataset's ranked leader holds 196 of the 1,833 records in scope, and the top five assignees combined account for 25.0% of all records. Beyond the top ten (32.0% combined), the ranking — which covers 100 companies total — thins into a long tail of entrants with only a handful of filings each. This pattern means a single dominant player exists, but the majority of activity comes from many smaller filers rather than a tight oligopoly.
Filing peaked in 2018 at 148 records and has since cooled: the last complete year, 2024, saw 86 filings, down 20% from 108 in 2021. That is a real slowdown, not just noise. However, figures for 2025 and 2026 are still incomplete because publication typically lags actual filing by around 18 months, so the most recent years will look stronger once they finish filling in.
G01N, covering material analysis and testing, appears in 57.7% of the 1,833 records — by far the most common classification. C12Q (enzyme and DNA testing, 28.5%) and B01L (lab apparatus, 25.0%) follow. Because records often carry multiple IPC classes, these percentages overlap rather than sum to 100%, and the pattern suggests most sorting claims are written to protect the downstream analytical step, not just the physical separation mechanism.
SG165165A1, filed by Cytonome/ST, claims a method and apparatus for isolating a subpopulation of cells with a desired phenotype from a mixed population using a microfluidic cell sorting device, then passing the isolated cells into a mixing and incubation region for exposure to a test compound. It is a representative early claim tying phenotype-based sorting directly to a downstream assay step. Anyone filing a sort-then-test workflow in a microfluidic device should check their claim language against this kind of phenotype-isolation-plus-incubation structure.
The technology composition data shows C40B (combinatorial chemistry libraries, 8.0% of records) and C07K (peptides and proteins, 6.5%) sit well below the dominant G01N, C12Q and B01L classes. That gap suggests sorting claims combined with combinatorial library screening or peptide-specific workflows are comparatively under-claimed relative to general analytical and lab-apparatus claims. A first claim there would likely combine a microfluidic sorting step with a specific combinatorial library readout, rather than a generic detection step.
Research Lab-on-a-Chip & Microfluidics: Microfluidic Cell Sorting Patent Landscape in depth with Eureka
Go past this page: query the whole lab-on-a-chip & microfluidics: microfluidic cell sorting patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.